空間基因組學和轉錄組學的全球市場：市場規模和佔有率分析（依技術、產品、應用和最終用戶）、收入估算和需求預測（截至 2030 年）

主要亮點

到 2023 年，空間基因組學和轉錄組學市場價值將達到 4.205 億美元，此後將以 18.2% 的複合年增長率擴大到 2030 年的 13.485 億美元。這項發展的主要原因是： - 臨床診斷、載體篩檢和藥物發現對這些技術的需求不斷增加，以及遺傳疾病數量的迅速增加。

多年來，空間基因組學和轉錄組學的主要應用已從研究轉向藥物發現和開發。空間方法現在被用來增進對癌症、神經系統疾病和傳染病的瞭解。這些技術也可能滿足對反應預測生物標記的需求，這是癌症患者未滿足的重要臨床需求。透過提高我們對腫瘤微環境的瞭解，這些生物標記可以幫助免疫療法的發展。

隨著生命科學領域的研究活動變得更加活躍，正在開發和臨床試驗的藥物管線也不斷增加。由於需要有效治療的慢性病和傳染病數量不斷增加，各國政府正在資助生命科學研究和開發計畫。生命科學研究事業得到了巨大的投資，帶來了前所未有的科學進步。

市場洞察

北美是最大的市場，到 2023 年所佔佔有率約為 45%，預計未來幾年將出現更強勁的增長。這是由於生物技術和製藥行業的高研發活動，以及非洲大陸慢性病風險的增加。此外，非洲大陸擁有聲譽卓著的醫療機構，政府也致力於發展研發設施。

預計亞太地區未來幾年將以最快的速度成長。這是由於該地區的全球和國內公司對生命科學研究的投資增加，以及傳染病和慢性病發病率的飆升。

未來幾年，藥物發現類別預計將以複合年增長率約 20% 的速度快速發展。旨在發現新藥的生物技術和藥物研究廣泛開展，學術機構和公司之間開發新藥的合作關係也在增加。

診斷和疾病分析將在未來幾年內實現最高的複合年增長率。這是因為已經開發了專門的軟體和工具來進行診斷。

耗材品類預計到2023年將以60%的佔有率引領業界，並在未來10年繼續引領業界。許多相關應用越來越多地使用試劑盒、試劑和各種其他消耗品，進一步推動了這個類別的成長。

到 2023 年，學術/研究機構類別將成為最大的細分市場，佔據 40% 的佔有率，而這一趨勢預計將在未來 10 年持續下去。這可能是因為空間基因組調查更頻繁地在學術研究機構中進行，以綜合分析各種疾病。

在本報告中，我們分析了全球空間基因組學和轉錄組學市場，包括市場的基本結構和最新情況、主要推動和抑制因素，以及全球、依地區和主要領域的市場規模趨勢展望（基於金額，2017-2030），我們依技術、產品、應用和最終用戶、當前市場競爭狀況以及主要公司的概況調查詳細趨勢。

目錄

第一章研究範圍

第二章研究方法

第 3 章執行摘要

第 4 章市場指標

第五章產業展望

• 市場動態
  • 趨勢
  • 促進因素
  • 抑制因素/課題
  • 促進/抑制因子影響分析
• 新型冠狀病毒感染 (COVID-19) 的影響
• 波特五力分析

第六章世界市場

• 摘要
• 市場收入：依技術劃分（2017-2030 年）
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依應用劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依地區劃分（2017-2030 年）

第七章北美市場

• 摘要
• 市場收入：依技術劃分（2017-2030 年）
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依應用劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）
• 市場收入：依國家/地區劃分（2017-2030 年）

第8章歐洲市場

第9章亞太市場

第10章拉丁美洲市場

第十一章中東非洲市場

第12章美國市場

• 概述
• 市場收入：依技術劃分（2017-2030 年）
• 市場收入：依產品分類（2017-2030 年）
• 市場收入：依應用劃分（2017-2030 年）
• 市場收入：以最終用戶劃分（2017-2030 年）

第十三章加拿大市場

第14章德國市場

第十五章法國市場

第十六章英國市場

第十七章義大利市場

第十八章西班牙市場

第十九章日本市場

第20章中國市場

第21章印度市場

第22章澳洲市場

第23章韓國市場

第24章巴西市場

第25章墨西哥市場

第26章沙烏地阿拉伯市場

第27章南非市場

第 28 章阿聯酋 (UAE) 市場

第29章競爭態勢

• 市場參與者及其產品列表
• 主要公司的競爭基準
• 各大公司的產品基準
• 近期策略發展狀況

第30章公司簡介

• NanoString Technologies Inc.
• 10x Genomics Inc.
• Illumina Inc.
• Bio-Rad Laboratories Inc.
• PerkinElmer Inc.
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Cantata Bio LLC
• S2 Genomics Inc.
• Natera Inc.
• Seven Bridges Genomics Inc.

第31章附錄

Key Highlights

The spatial genomics & transcriptomics market was valued at USD 420.5 million in 2023, and it will rise to USD 1,348.5 million, powering at an 18.2% compound annual growth rate, by 2030.

This development is mainly because of the rising demand for these technologies for clinical diagnostics, carrier screening, and drug discovery, and the surging occurrence of genetic disorders.

Over the years, the main applications of spatial genomics and transcriptomics have shifted from research to drug discovery & development.

Now, spatial methods are being employed to enhance the understanding of cancer, neurological illnesses, and infections.

The need for predictive biomarkers of response, which are a key unmet clinical requirement of cancer patients, is also likely to be addressed by these technologies.

By improving the knowledge of the tumor microenvironment, these biomarkers assist in developing immunotherapies.

With the rising research activities in life sciences, the total pipeline activity in terms of underdevelopment drugs as well as clinical trials has increased.

Governments are funding in life sciences research & development projects because of the increasing incidence of chronic and infectious illnesses, which require efficient treatments.

Life sciences research undertakings are getting exceptional investment and resulting in scientific improvements like never before, with which substantially more medications than before have made it to the industry in the last few years.

Market Insights

North America was the largest contributor to the industry in 2023, with around 45% share, and it is likely to further propel at a robust rate in the coming years.

This is because of the significant R&D activities in the biotechnology and pharmaceutical industries, along with the increasing risk of chronic illnesses in this continent.

This expansion is also because of the presence of reputable healthcare organizations and a robust government emphasis on the development of R&D facilities in this continent.

APAC will propel at the fastest rate in the years to come. This will be because of the rising investment from both global and domestic firms in this region in life science research, and the surging incidence of infectious and chronic diseases.

The drug discovery category will advance at a faster CAGR, of approximately 20%, in the coming years.

The broad biotech and pharma research on track for the finding of new drugs and the increasing number of partnerships between the academic institutes and industry players for drug development.

Diagnostics and illness profiling will propel at the highest compound annual growth rate in the coming years. This is because of the development of specialized software and tools for diagnostics.

The consumables category led the industry in 2023, with a 60% share, and it will remain leading throughout this decade.

The increasing utilization of kits, reagents, and various other consumables for many associated applications further boost this category expansion.

The academic and research institutes category was the largest contributor in 2023, with a 40% share, and it is likely to continue this trend throughout this decade.

This can be because spatial genomic studies are being conducted more often in academic research facilities for a comprehensive analysis of different illnesses.

Table of Contents

Chapter 1. Research Scope

• 1.1. Research Objectives
• 1.2. Market Definition
• 1.3. Analysis Period
• 1.4. Market Size Breakdown by Segments
  • 1.4.1. Market size breakdown, by technique
  • 1.4.2. Market size breakdown, by product
  • 1.4.3. Market size breakdown, by application
  • 1.4.4. Market size breakdown, by end user
  • 1.4.5. Market size breakdown, by region
  • 1.4.6. Market size breakdown, by country
• 1.5. Market Data Reporting Unit
  • 1.5.1. Value
• 1.6. Key Stakeholders

Chapter 2. Research Methodology

• 2.1. Secondary Research
  • 2.1.1. Paid
  • 2.1.2. Unpaid
  • 2.1.3. P&S Intelligence database
• 2.2. Primary Research
• 2.3. Market Size Estimation
• 2.4. Data Triangulation
• 2.5. Currency Conversion Rates
• 2.6. Assumptions for the Study
• 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

• 5.1. Market Dynamics
  • 5.1.1. Trends
  • 5.1.2. Drivers
  • 5.1.3. Restraints/challenges
  • 5.1.4. Impact analysis of drivers/restraints
• 5.2. Impact of COVID-19
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Bargaining power of buyers
  • 5.3.2. Bargaining power of suppliers
  • 5.3.3. Threat of new entrants
  • 5.3.4. Intensity of rivalry
  • 5.3.5. Threat of substitutes

Chapter 6. Global Market

• 6.1. Overview
• 6.2. Market Revenue, by Technology (2017-2030)
• 6.3. Market Revenue, by Product (2017-2030)
• 6.4. Market Revenue, by Application (2017-2030)
• 6.5. Market Revenue, by End User (2017-2030)
• 6.6. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

• 7.1. Overview
• 7.2. Market Revenue, by Technology (2017-2030)
• 7.3. Market Revenue, by Product (2017-2030)
• 7.4. Market Revenue, by Application (2017-2030)
• 7.5. Market Revenue, by End User (2017-2030)
• 7.6. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

• 8.1. Overview
• 8.2. Market Revenue, by Technology (2017-2030)
• 8.3. Market Revenue, by Product (2017-2030)
• 8.4. Market Revenue, by Application (2017-2030)
• 8.5. Market Revenue, by End User (2017-2030)
• 8.6. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

• 9.1. Overview
• 9.2. Market Revenue, by Technology (2017-2030)
• 9.3. Market Revenue, by Product (2017-2030)
• 9.4. Market Revenue, by Application (2017-2030)
• 9.5. Market Revenue, by End User (2017-2030)
• 9.6. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

• 10.1. Overview
• 10.2. Market Revenue, by Technology (2017-2030)
• 10.3. Market Revenue, by Product (2017-2030)
• 10.4. Market Revenue, by Application (2017-2030)
• 10.5. Market Revenue, by End User (2017-2030)
• 10.6. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

• 11.1. Overview
• 11.2. Market Revenue, by Technology (2017-2030)
• 11.3. Market Revenue, by Product (2017-2030)
• 11.4. Market Revenue, by Application (2017-2030)
• 11.5. Market Revenue, by End User (2017-2030)
• 11.6. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

• 12.1. Overview
• 12.2. Market Revenue, by Technology (2017-2030)
• 12.3. Market Revenue, by Product (2017-2030)
• 12.4. Market Revenue, by Application (2017-2030)
• 12.5. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

• 13.1. Overview
• 13.2. Market Revenue, by Technology (2017-2030)
• 13.3. Market Revenue, by Product (2017-2030)
• 13.4. Market Revenue, by Application (2017-2030)
• 13.5. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

• 14.1. Overview
• 14.2. Market Revenue, by Technology (2017-2030)
• 14.3. Market Revenue, by Product (2017-2030)
• 14.4. Market Revenue, by Application (2017-2030)
• 14.5. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

• 15.1. Overview
• 15.2. Market Revenue, by Technology (2017-2030)
• 15.3. Market Revenue, by Product (2017-2030)
• 15.4. Market Revenue, by Application (2017-2030)
• 15.5. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

• 16.1. Overview
• 16.2. Market Revenue, by Technology (2017-2030)
• 16.3. Market Revenue, by Product (2017-2030)
• 16.4. Market Revenue, by Application (2017-2030)
• 16.5. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

• 17.1. Overview
• 17.2. Market Revenue, by Technology (2017-2030)
• 17.3. Market Revenue, by Product (2017-2030)
• 17.4. Market Revenue, by Application (2017-2030)
• 17.5. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

• 18.1. Overview
• 18.2. Market Revenue, by Technology (2017-2030)
• 18.3. Market Revenue, by Product (2017-2030)
• 18.4. Market Revenue, by Application (2017-2030)
• 18.5. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

• 19.1. Overview
• 19.2. Market Revenue, by Technology (2017-2030)
• 19.3. Market Revenue, by Product (2017-2030)
• 19.4. Market Revenue, by Application (2017-2030)
• 19.5. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

• 20.1. Overview
• 20.2. Market Revenue, by Technology (2017-2030)
• 20.3. Market Revenue, by Product (2017-2030)
• 20.4. Market Revenue, by Application (2017-2030)
• 20.5. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

• 21.1. Overview
• 21.2. Market Revenue, by Technology (2017-2030)
• 21.3. Market Revenue, by Product (2017-2030)
• 21.4. Market Revenue, by Application (2017-2030)
• 21.5. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

• 22.1. Overview
• 22.2. Market Revenue, by Technology (2017-2030)
• 22.3. Market Revenue, by Product (2017-2030)
• 22.4. Market Revenue, by Application (2017-2030)
• 22.5. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

• 23.1. Overview
• 23.2. Market Revenue, by Technology (2017-2030)
• 23.3. Market Revenue, by Product (2017-2030)
• 23.4. Market Revenue, by Application (2017-2030)
• 23.5. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

• 24.1. Overview
• 24.2. Market Revenue, by Technology (2017-2030)
• 24.3. Market Revenue, by Product (2017-2030)
• 24.4. Market Revenue, by Application (2017-2030)
• 24.5. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

• 25.1. Overview
• 25.2. Market Revenue, by Technology (2017-2030)
• 25.3. Market Revenue, by Product (2017-2030)
• 25.4. Market Revenue, by Application (2017-2030)
• 25.5. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

• 26.1. Overview
• 26.2. Market Revenue, by Technology (2017-2030)
• 26.3. Market Revenue, by Product (2017-2030)
• 26.4. Market Revenue, by Application (2017-2030)
• 26.5. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

• 27.1. Overview
• 27.2. Market Revenue, by Technology (2017-2030)
• 27.3. Market Revenue, by Product (2017-2030)
• 27.4. Market Revenue, by Application (2017-2030)
• 27.5. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

• 28.1. Overview
• 28.2. Market Revenue, by Technology (2017-2030)
• 28.3. Market Revenue, by Product (2017-2030)
• 28.4. Market Revenue, by Application (2017-2030)
• 28.5. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

• 29.1. List of Market Players and their Offerings
• 29.2. Competitive Benchmarking of Key Players
• 29.3. Product Benchmarking of Key Players
• 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

• 30.1. NanoString Technologies Inc.
  • 30.1.1. Business overview
  • 30.1.2. Product and service offerings
  • 30.1.3. Key financial summary
• 30.2. 10x Genomics Inc.
  • 30.2.1. Business overview
  • 30.2.2. Product and service offerings
  • 30.2.3. Key financial summary
• 30.3. Illumina Inc.
  • 30.3.1. Business overview
  • 30.3.2. Product and service offerings
  • 30.3.3. Key financial summary
• 30.4. Bio-Rad Laboratories Inc.
  • 30.4.1. Business overview
  • 30.4.2. Product and service offerings
  • 30.4.3. Key financial summary
• 30.5. PerkinElmer Inc.
  • 30.5.1. Business overview
  • 30.5.2. Product and service offerings
  • 30.5.3. Key financial summary
• 30.6. Thermo Fisher Scientific Inc.
  • 30.6.1. Business overview
  • 30.6.2. Product and service offerings
  • 30.6.3. Key financial summary
• 30.7. F. Hoffmann-La Roche Ltd.
  • 30.7.1. Business overview
  • 30.7.2. Product and service offerings
  • 30.7.3. Key financial summary
• 30.8. Cantata Bio LLC
  • 30.8.1. Business overview
  • 30.8.2. Product and service offerings
  • 30.8.3. Key financial summary
• 30.9. S2 Genomics Inc.
  • 30.9.1. Business overview
  • 30.9.2. Product and service offerings
  • 30.9.3. Key financial summary
• 30.10. Natera Inc.
  • 30.10.1. Business overview
  • 30.10.2. Product and service offerings
  • 30.10.3. Key financial summary
• 30.11. Seven Bridges Genomics Inc.
  • 30.11.1. Business overview
  • 30.11.2. Product and service offerings
  • 30.11.3. Key financial summary

Chapter 31. Appendix

• 31.1. Abbreviations
• 31.2. Sources and References
• 31.3. Related Reports